A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1962-1971

  Michaux, Alexandre ^a,b   Larrieu, Pierre ^a,b   Stroobant, Vincent ^a,b   Fonteneau, Jean François ^c,d,e   Jotereau, Francine ^c,d,e   Van Den Eynde, Benoît J ^a,b   Moreau Aubry, Agnès ^c,d,e   Vigneron, Nathalie ^a,b  

^a DE DUVE INSTITUTE   (Belgium)

^b Walloon Excellence in Life Sciences and Biotechnology   (Belgium)

^c INSERM   (France)

^d CNRS   (France)

^e UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HLA A3 ANTIGEN; MELANOCYTE PROTEIN PMEL 17; NUCLEOPHILE; PROTEASOME;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS7; CONTROLLED STUDY; ELECTROPORATION; ENZYME ACTIVE SITE; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MELANOMA CELL; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; GP100 MELANOMA ANTIGEN; HLA-A3 ANTIGEN; HUMANS; MELANOMA; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SPLICING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84896724501     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302032     Document Type: Article

References (44)

1. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
2. Vigneron, N., and B. J. Van den Eynde. 2011. Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Cell. Mol. Life Sci. 68: 1503-1520.
3. Vigneron, N., V. Stroobant, B. J. Van den Eynde, and P. van der Bruggen. 2013. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 13: 15-20.
4. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
5. De Plaen, E., K. Arden, C. Traversari, J. J. Gaforio, J.-P. Szikora, C. De Smet, F. Brasseur, P. van der Bruggen, B. Lethé, C. Lurquin, et al. 1994. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40: 360-369.
6. Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethé, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489-495.
7. Wölfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. H. Meyer zum Büschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24: 759-764.
8. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154: 3961-3968.
9. Vigneron, N., A. Ooms, S. Morel, W. Ma, G. Degiovanni, and B. J. Van den Eynde. 2005. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells. Tissue Antigens 65: 156-162.
10. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethé, P. Romero, T. Boon, and J. C. Renauld. 1996. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J. Invest. Dermatol. 107: 63-67.
11. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352.
12. Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Büschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
13. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated beta-catenin gene encodes a melanomaspecific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185-1192.
14. Vigneron, N., A. Ooms, S. Morel, G. Degiovanni, and B. J. Van Den Eynde. 2002. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun. 2: 9.
15. Gaugler, B., N. Brouwenstijn, V. Vantomme, J. P. Szikora, C. W. Van der Spek, J. J. Patard, T. Boon, P. Schrier, and B. J. Van den Eynde. 1996. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44: 323-330.
16. Kessler, J. H., N. J. Beekman, S. A. Bres-Vloemans, P. Verdijk, P. A. van Veelen, A. M. Kloosterman-Joosten, D. C. Vissers, G. J. ten Bosch, M. G. Kester, A. Sijts, et al. 2001. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193: 73-88.
17. Moreau-Aubry, A., S. Le Guiner, N. Labarrière, M. C. Gesnel, F. Jotereau, and R. Breathnach. 2000. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J. Exp. Med. 191: 1617-1624.
18. Guilloux, Y., S. Lucas, V. G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethé, F. Jotereau, and T. Boon. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183: 1173-1183.
19. Van Den Eynde, B. J., B. Gaugler, M. Probst-Kepper, L. Michaux, O. Devuyst, F. Lorge, P. Weynants, and T. Boon. 1999. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J. Exp. Med. 190: 1793-1800.
20. Wang, R. F., M. R. Parkhurst, Y. Kawakami, P. F. Robbins, and S. A. Rosenberg. 1996. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183: 1131-1140.
21. Zarling, A. L., J. M. Polefrone, A. M. Evans, L. M. Mikesh, J. Shabanowitz, S. T. Lewis, V. H. Engelhard, and D. F. Hunt. 2006. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 103: 14889-14894.
22. Skipper, J. C., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, Jr., T. Boon, et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183: 527-534.
23. Mosse, C. A., L. Meadows, C. J. Luckey, D. J. Kittlesen, E. L. Huczko, C. L. Slingluff, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 1998. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187: 37-48.
24. Hanada, K., J. W. Yewdell, and J. C. Yang. 2004. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427: 252-256.
25. Vigneron, N., V. Stroobant, J. Chapiro, A. Ooms, G. Degiovanni, S. Morel, P. van der Bruggen, T. Boon, and B. J. Van den Eynde. 2004. An antigenic peptide produced by peptide splicing in the proteasome. Science 304: 587-590.
26. Dalet, A., P. F. Robbins, V. Stroobant, N. Vigneron, Y. F. Li, M. El-Gamil, K. Hanada, J. C. Yang, S. A. Rosenberg, and B. J. Van den Eynde. 2011. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl. Acad. Sci. USA 108: E323-E331.
27. Warren, E. H., N. J. Vigneron, M. A. Gavin, P. G. Coulie, V. Stroobant, A. Dalet, S. S. Tykodi, S. M. Xuereb, J. K. Mito, S. R. Riddell, and B. J. Van den Eynde. 2006. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313: 1444-1447.
28. Dalet, A., N. Vigneron, V. Stroobant, K. Hanada, and B. J. Van den Eynde. 2010. Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. J. Immunol. 184: 3016-3024.
29. Pandolfino, M. C., C. Viret, N. Gervois, Y. Guilloux, F. Davodeau, E. Diez, and F. Jotereau. 1992. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur. J. Immunol. 22: 1795-1802.
30. Uyttenhove, C., L. Pilotte, I. Théate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B. J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9: 1269-1274.
31. Labarriere, N., E. Diez, M. C. Pandolfino, C. Viret, Y. Guilloux, S. Le Guiner, J. F. Fonteneau, B. Dreno, and F. Jotereau. 1997. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J. Immunol. 158: 1238-1245.
32. Seed, B., and A. Aruffo. 1987. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA 84: 3365-3369.
33. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119: 203-210.
34. Traversari, C., P. van der Bruggen, B. Van den Eynde, P. Hainaut, C. Lemoine, N. Ohta, L. Old, and T. Boon. 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35: 145-152.
35. Adema, G. J., A. J. de Boer, A. M. Vogel, W. A. Loenen, and C. G. Figdor. 1994. Molecular characterization of the melanocyte lineage-specific antigen gp100. J. Biol. Chem. 269: 20126-20133.
36. Larrieu, P., L. H. Ouisse, Y. Guilloux, F. Jotereau, and J. F. Fonteneau. 2007. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes. Cancer Immunol. Immunother. 56: 1565-1575.
37. Chapiro, J., S. Claverol, F. Piette, W. Ma, V. Stroobant, B. Guillaume, J. E. Gairin, S. Morel, O. Burlet-Schiltz, B. Monsarrat, et al. 2006. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176: 1053-1061.
38. Moreau-Aubry, A., J. Fonteneau, N. Labarriere, F. Jotereau, E. Houssaint, and R. Breathnach. 1997. Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes. Int. J. Oncol. 10: 841-846.
39. Mishto, M., A. Goede, K. T. Taube, C. Keller, K. Janek, P. Henklein, A. Niewienda, A. Kloss, S. Gohlke, B. Dahlmann, et al. 2012. Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Mol. Cell. Proteomics 11: 1008-1023.
40. Groll, M., M. Götz, M. Kaiser, E. Weyher, and L. Moroder. 2006. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol. 13: 607-614.
41. Groll, M., L. Ditzel, J. Löwe, D. Stock, M. Bochtler, H. D. Bartunik, and R. Huber. 1997. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386: 463-471.
42. Tenzer, S., B. Peters, S. Bulik, O. Schoor, C. Lemmel, M. M. Schatz, P. M. Kloetzel, H. G. Rammensee, H. Schild, and H. G. Holzhütter. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell. Mol. Life Sci. 62: 1025-1037.
43. Tenzer, S., L. Stoltze, B. Schönfisch, J. Dengjel, M. Müller, S. Stevanović, H. G. Rammensee, and H. Schild. 2004. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J. Immunol. 172: 1083-1091.
44. Liepe, J., M. Mishto, K. Textoris-Taube, K. Janek, C. Keller, P. Henklein, P. M. Kloetzel, and A. Zaikin. 2010. The 20S proteasome splicing activity discovered by SpliceMet. PLOS Comput. Biol. 6: e1000830.